Specialty Pharmacy

If approved, Xeljanz will be the first Janus kinase inhibitor for psoriatic arthritis.

Pilot project to bring pre-exposure prophylaxis to the Philippines for the first time.

A look at last week's top stories in the world of pharmacy.

Top news of the day from across the health care landscape.

Durvalumab is indicated to treat patients with locally-advanced, unresectable non-small cell lung cancer.

Targeting cell mutations could disrupt tumor cell growth without harming non-cancerous cells.

With a shift from intravenous to self-administered medication, specialty pharmacists are key in patient education.

Combination therapy cuts standard HCV treatment regimen from 12 weeks to 8 weeks.

Mike Agostino, RPh, president at Amber Pharmacy, president-elect at NASP, talks about the exciting things for this year's NASP Annual Meeting, including keynote speaker, Alex Azar, former president at Eli Lilly.

Rebecca Shanahan, JD, chief executive officer of Avella Specialty and president of the National Association of Specialty Pharmacy speaks out on direct and indirect remuneration fees in a 3-part interview.

An approval decision for Alecensa is expected by November 30, 2017.

Sirukumab is designed to treat adults with moderately-to-severely active rheumatoid arthritis.

Research advances hunt for a safe and effective preventative HIV vaccine.

Vyxeos is indicated to treat newly diagnosed therapy-related AML or AML with myelodysplasia-related changes.

Three weeks of radiation post-mastectomy observed to be safe and effective for breast cancer patients.

The approach only targets metastatic tissue, reducing negative adverse events associated with chemotherapy.

Top news of the day from across the health care landscape.

HEV is reemerging as a zoonotic virus, with individuals becoming infected via pigs and pork products.

Bacterium may hold the key to preventing resistance to chemotherapy.

Imbruvica is the first FDA-approved therapy to treat cGVHD.

Scientists say ring containing pre-exposure prophylaxis and Truvada is safe in US teens, now need data in African adolescent girls.

The label has been updated to include data from adults co-infected with hepatitis C virus and HIV-1.

Jon Gavras, MD, chief medical officer at Prime Therapeutics, explores how combining medical and pharmacy benefits could result in a better understanding of a certain drug's value.

Top news of the day from across the health care landscape.

The first of a 2-part series on the influential women shaping the specialty pharmacy industry.

Nivolumab approved for form of metastatic colorectal cancer that typically does not respond to chemotherapy.

Enasidenib, an oral inhibitor for relapsed or refractory acute myeloid leukemia, shows promise in achieving a complete response with hematologic improvement.

New treatment strategies for rheumatoid arthritis led to a reduction in congestive heart failure and cardiovascular mortality after the year 2000.

Combining old and new technology may provide superior oncologic outcomes for patients with resectable lung cancer.

Study will compare the pharmacokinetics and clinical outcomes between Humira biosimilar and its reference product in the treatment of moderate-to-severe chronic plaque psoriasis.